Invivyd Inc (IVVD)

$0.89 +0.04 (4.61%)
Market Cap 263.32M
Revenue (ttm) 53.43M
Net Income (ttm) -52.49M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -98.24%
Debt to Equity Ratio 0.00
Volume 2,202,900
Avg Vol 4,384,000
Day's Range N/A - N/A
Shares Out 294.61M
Stochastic %K 41%
Beta 0.67
Analysts Strong Sell
Price Target $10.00

Company Profile

Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 819 0080
Address:
209 Church Street, New Haven, United States
UserID123456
UserID123456 Jul. 3 at 1:21 PM
$IVVD Why is this up? In a purely politically motivated move (shocking) our idiotic leader of the HHS has officially ended all COVID-19 emergency use authorization declarations. They’re giving a 12-month “advance notice” / grace period to manufacturers of drugs or biological products, and a 6-month period to manufacturers of medical devices, to shift to full approval/clearance. That means Pemgarda is cooked.
1 · Reply
gb2017384
gb2017384 Jun. 29 at 3:08 PM
$IVVD DO THESE INSIDE TRADERS KNOW SOMETHING WE SHOULD$.
3 · Reply
gb2017384
gb2017384 Jun. 29 at 1:45 PM
$IVVD ,I KNOW IF THIS IVVD STOCK TAKES A DUMP THERES GOING TO BE ALOT OF BANKRUPT INVESTORS ÷$$$$$$$$$$$$$$$$$$$$$$$$$$$$$.
0 · Reply
billsmall
billsmall Jun. 26 at 10:25 PM
$IVVD OK at 3:59 there was a 22 mil share trade. Was that you Nik bringing your SLS profits over LOL (Congratulations by the way) I have to admit I'm a bit perplexed how this is trading. Anyone?
2 · Reply
Rynr
Rynr Jun. 25 at 2:34 AM
$IVVD silence before the storm
1 · Reply
student56
student56 Jun. 18 at 3:17 PM
$IVVD go higher
0 · Reply
Rollercoaster22
Rollercoaster22 Jun. 18 at 2:33 PM
$IVVD Very
0 · Reply
alexx013
alexx013 Jun. 18 at 2:26 PM
$IVVD dollar
0 · Reply
billsmall
billsmall Jun. 18 at 1:57 PM
$IVVD Someone smarter than me have a comment on why I'm seeing over 52k open $7.50 Puts? Not sure when they were written or bought just find it strange because no other strikes are anywhere near than in the near term
0 · Reply
Richi_B
Richi_B Jun. 18 at 11:03 AM
$IVVD had to average down at these prices. I will try and get more, this goes in circles. Back to around $2.50 in winter, hopefully more.
1 · Reply
Latest News on IVVD
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 2, 2026, 7:01 AM EDT - 2 days ago

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer

Jun 29, 2026, 7:00 AM EDT - 5 days ago

NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer

NBP

Invivyd completes enrollment of LIBERTY clinical trial

2026-06-16T11:37:10.000Z - 18 days ago

Invivyd completes enrollment of LIBERTY clinical trial

Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine

Jun 16, 2026, 7:01 AM EDT - 18 days ago

Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine

Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine Co-Administration

Jun 9, 2026, 7:01 AM EDT - 25 days ago

Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine Co-Administration

Invivyd Transcript: H.C. Wainwright “HCW @ Home” Series

Jun 8, 2026, 10:00 AM EDT - 26 days ago

Invivyd Transcript: H.C. Wainwright “HCW @ Home” Series

Invivyd Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 4:55 PM EDT - 4 weeks ago

Invivyd Transcript: Jefferies Global Healthcare Conference 2026

Invivyd completes enrollment in DECLARATION trial

2026-06-01T11:06:59.000Z - 4 weeks ago

Invivyd completes enrollment in DECLARATION trial

Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID

Jun 1, 2026, 7:01 AM EDT - 4 weeks ago

Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID

Invivyd to Participate in Upcoming Investor Events

May 27, 2026, 7:01 AM EDT - 5 weeks ago

Invivyd to Participate in Upcoming Investor Events

Invivyd management to meet with BTIG

2026-05-19T19:50:10.000Z - 6 weeks ago

Invivyd management to meet with BTIG

Invivyd Transcript: AGM 2026

May 19, 2026, 8:30 AM EDT - 6 weeks ago

Invivyd Transcript: AGM 2026

Invivyd post earnings selloff overdone, says H.C. Wainwright

2026-05-14T19:05:42.000Z - 7 weeks ago

Invivyd post earnings selloff overdone, says H.C. Wainwright

Invivyd Earnings Call Transcript: Q1 2026

May 14, 2026, 8:30 AM EDT - 7 weeks ago

Invivyd Earnings Call Transcript: Q1 2026

Invivyd Earnings release: Q1 2026

May 14, 2026, 8:30 AM EDT - 7 weeks ago

Invivyd Earnings release: Q1 2026

Invivyd Slides: Q1 2026

May 14, 2026, 8:30 AM EDT - 7 weeks ago

Invivyd Slides: Q1 2026

Invivyd Quarterly report: Q1 2026

May 14, 2026, 8:30 AM EDT - 7 weeks ago

Invivyd Quarterly report: Q1 2026

Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights

May 14, 2026, 7:01 AM EDT - 7 weeks ago

Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights

Invivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of COVID Monoclonal Antibody and Comparing Results to COVID Vaccination

May 11, 2026, 7:01 AM EDT - 7 weeks ago

Invivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of COVID Monoclonal Antibody and Comparing Results to COVID Vaccination

Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026

May 7, 2026, 7:01 AM EDT - 2 months ago

Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026

Invivyd annouces Chairman Elia to speak at POLITICO Health Care Summit

2026-04-20T11:28:23.000Z - 2 months ago

Invivyd annouces Chairman Elia to speak at POLITICO Health Care Summit

Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit

Apr 20, 2026, 7:01 AM EDT - 2 months ago

Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit

Invivyd provides update on Phase 3 DECLARATION study of VYD2311

2026-04-09T13:34:05.000Z - 3 months ago

Invivyd provides update on Phase 3 DECLARATION study of VYD2311

Invivyd announces discovery, advancement of measles antibody candidate VMS063

2026-04-09T13:33:36.000Z - 3 months ago

Invivyd announces discovery, advancement of measles antibody candidate VMS063

Invivyd Transcript: Study update

Apr 9, 2026, 8:30 AM EDT - 3 months ago

Invivyd Transcript: Study update

Invivyd Press release: Study update

Apr 9, 2026, 8:30 AM EDT - 3 months ago

Invivyd Press release: Study update

Invivyd Slides: Study update

Apr 9, 2026, 8:30 AM EDT - 3 months ago

Invivyd Slides: Study update

Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles

Apr 9, 2026, 7:01 AM EDT - 3 months ago

Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles

Invivyd Proxy statement: Proxy filing

Apr 6, 2026, 8:00 AM EDT - 3 months ago

Invivyd Proxy statement: Proxy filing

Invivyd Proxy statement: Proxy filing

Apr 6, 2026, 8:00 AM EDT - 3 months ago

Invivyd Proxy statement: Proxy filing

Invivyd Announces Presentation at the World Vaccine Congress Washington

Mar 30, 2026, 4:05 PM EDT - 3 months ago

Invivyd Announces Presentation at the World Vaccine Congress Washington

Invivyd Earnings Call Transcript: Q4 2025

Mar 5, 2026, 8:30 AM EST - 4 months ago

Invivyd Earnings Call Transcript: Q4 2025

Invivyd Annual report: Q4 2025

Mar 5, 2026, 8:30 AM EST - 4 months ago

Invivyd Annual report: Q4 2025

Invivyd Earnings release: Q4 2025

Mar 5, 2026, 8:30 AM EST - 4 months ago

Invivyd Earnings release: Q4 2025

Invivyd Slides: Q4 2025

Mar 5, 2026, 8:30 AM EST - 4 months ago

Invivyd Slides: Q4 2025

Invivyd reports cash, cash equivalents of $226.7M as of December 31

2026-03-05T12:20:54.000Z - 4 months ago

Invivyd reports cash, cash equivalents of $226.7M as of December 31

Invivyd appoints Michael Mina as CMO

2026-03-05T12:20:37.000Z - 4 months ago

Invivyd appoints Michael Mina as CMO

Invivyd reports FY25 EPS (30c) vs. ($1.43) last year

2026-03-05T12:13:36.000Z - 4 months ago

Invivyd reports FY25 EPS (30c) vs. ($1.43) last year

Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates

Mar 5, 2026, 7:03 AM EST - 4 months ago

Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates

Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer

Mar 5, 2026, 7:01 AM EST - 4 months ago

Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer

Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026

Mar 2, 2026, 4:10 PM EST - 4 months ago

Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026

Invivyd announces peer-reviewed publication using CANOPY trial data

2026-02-24T12:48:12.000Z - 4 months ago

Invivyd announces peer-reviewed publication using CANOPY trial data

New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies

Feb 24, 2026, 7:01 AM EST - 4 months ago

New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies

Invivyd management to meet virtually with BTIG

2026-02-18T17:40:26.000Z - 4 months ago

Invivyd management to meet virtually with BTIG

Invivyd aligns with FDA on LIBERTY Phase 3 trial of VYD2311

2026-02-03T12:05:43.000Z - 5 months ago

Invivyd aligns with FDA on LIBERTY Phase 3 trial of VYD2311

Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration

Feb 3, 2026, 7:01 AM EST - 5 months ago

Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration

Invivyd announces partnership with ski champion Lindsey Vonn

2026-01-22T12:16:53.000Z - 5 months ago

Invivyd announces partnership with ski champion Lindsey Vonn

Invivyd, SPEAR Study Group plan to initiate Phase 2 trial of VYD2311

2026-01-20T12:11:41.000Z - 5 months ago

Invivyd, SPEAR Study Group plan to initiate Phase 2 trial of VYD2311

Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026

Jan 20, 2026, 7:01 AM EST - 5 months ago

Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026

Invivyd reports preliminary Q4 PEMGARDA net product revenue of $17.2M

2026-01-08T12:12:15.000Z - 6 months ago

Invivyd reports preliminary Q4 PEMGARDA net product revenue of $17.2M

Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights

Jan 8, 2026, 7:01 AM EST - 6 months ago

Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights

Invivyd Slides: Corporate Presentation

Jan 8, 2026, 7:00 AM EST - 6 months ago

Invivyd Slides: Corporate Presentation

Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Dec 23, 2025, 7:05 AM EST - 6 months ago

Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Dec 23, 2025, 7:01 AM EST - 6 months ago

Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Invivyd Registration statement: Registration Filing

Dec 19, 2025, 7:00 AM EST - 7 months ago

Invivyd Registration statement: Registration Filing

Invivyd Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 2:35 PM EST - 7 months ago

Invivyd Transcript: Evercore ISI 8th Annual HealthCONx Conference

Invivyd to Participate at the 8th Annual Evercore Healthcare Conference

Nov 25, 2025, 7:01 AM EST - 7 months ago

Invivyd to Participate at the 8th Annual Evercore Healthcare Conference

Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness

Nov 24, 2025, 7:01 AM EST - 7 months ago

Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness

Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants

Nov 17, 2025, 10:40 PM EST - 8 months ago

Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants

Invivyd Announces Proposed Public Offering of Common Stock

Nov 17, 2025, 4:01 PM EST - 8 months ago

Invivyd Announces Proposed Public Offering of Common Stock

Invivyd Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:30 AM EST - 8 months ago

Invivyd Earnings Call Transcript: Q3 2025

Invivyd Quarterly report: Q3 2025

Nov 6, 2025, 8:30 AM EST - 8 months ago

Invivyd Quarterly report: Q3 2025

Invivyd Earnings release: Q3 2025

Nov 6, 2025, 8:30 AM EST - 8 months ago

Invivyd Earnings release: Q3 2025

Invivyd Slides: Q3 2025

Nov 6, 2025, 8:30 AM EST - 8 months ago

Invivyd Slides: Q3 2025

Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 6, 2025, 7:01 AM EST - 8 months ago

Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Invivyd to Host Third Quarter 2025 Financial Results and Corporate Update Call on November 6, 2025

Nov 3, 2025, 4:01 PM EST - 8 months ago

Invivyd to Host Third Quarter 2025 Financial Results and Corporate Update Call on November 6, 2025

Invivyd Transcript: Study Update

Oct 30, 2025, 8:30 AM EDT - 8 months ago

Invivyd Transcript: Study Update

Invivyd Press release: Study Update

Oct 30, 2025, 8:30 AM EDT - 8 months ago

Invivyd Press release: Study Update

Invivyd Slides: Study Update

Oct 30, 2025, 8:30 AM EDT - 8 months ago

Invivyd Slides: Study Update

Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Oct 28, 2025, 7:01 AM EDT - 8 months ago

Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Oct 6, 2025, 7:01 AM EDT - 9 months ago

Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Invivyd Registration statement: Registration Filing

Oct 2, 2025, 8:00 AM EDT - 9 months ago

Invivyd Registration statement: Registration Filing

Invivyd Appoints Paul B. Bolno, M.D.

Sep 24, 2025, 4:01 PM EDT - 10 months ago

Invivyd Appoints Paul B. Bolno, M.D.

Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer

Sep 17, 2025, 7:01 AM EDT - 10 months ago

Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer

Invivyd Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 12:00 PM EDT - 10 months ago

Invivyd Transcript: H.C. Wainwright 27th Annual Global Investment Conference

SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd's VYD2311 At RECOVER-TLC Workshop September 9-10, 2025

Sep 4, 2025, 7:01 AM EDT - 10 months ago

SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd's VYD2311 At RECOVER-TLC Workshop September 9-10, 2025

Invivyd Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 2:10 PM EDT - 10 months ago

Invivyd Transcript: Cantor Global Healthcare Conference 2025

Invivyd to Participate in Upcoming Investor Conferences

Aug 27, 2025, 7:01 AM EDT - 11 months ago

Invivyd to Participate in Upcoming Investor Conferences

Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter's Option to Purchase Additional Shares

Aug 22, 2025, 12:00 PM EDT - 11 months ago

Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter's Option to Purchase Additional Shares

Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants

Aug 20, 2025, 11:58 PM EDT - 11 months ago

Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants

Invivyd Announces Continued Neutralizing Activity of PEMGARDA® (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG (“Stratus”)

Aug 18, 2025, 4:32 PM EDT - 11 months ago

Invivyd Announces Continued Neutralizing Activity of PEMGARDA® (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG (“Stratus”)

Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 14, 2025, 4:49 PM EDT - 11 months ago

Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19

Aug 14, 2025, 4:47 PM EDT - 11 months ago

Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19

Invivyd Quarterly report: Q2 2025

Aug 14, 2025, 9:30 AM EDT - 11 months ago

Invivyd Quarterly report: Q2 2025

Invivyd Earnings release: Q2 2025

Aug 14, 2025, 9:30 AM EDT - 11 months ago

Invivyd Earnings release: Q2 2025

Invivyd Slides: Q2 2025

Aug 14, 2025, 9:30 AM EDT - 11 months ago

Invivyd Slides: Q2 2025

Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome

Jul 23, 2025, 7:01 AM EDT - 1 year ago

Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome

National Comprehensive Cancer Network® (NCCN®) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe Impact of COVID-19 on This Population

Jul 21, 2025, 7:05 AM EDT - 1 year ago

National Comprehensive Cancer Network® (NCCN®) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe Impact of COVID-19 on This Population

Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome

Jul 2, 2025, 7:01 AM EDT - 1 year ago

Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome

Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection

Jun 26, 2025, 7:01 AM EDT - 1 year ago

Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection

Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus

May 27, 2025, 7:01 AM EDT - 1 year ago

Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus

Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

May 23, 2025, 7:01 AM EDT - 1 year ago

Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19

May 21, 2025, 9:30 AM EDT - 1 year ago

Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19

Invivyd Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 20, 2025, 11:00 AM EDT - 1 year ago

Invivyd Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

Invivyd Earnings Call Transcript: Q1 2025

May 15, 2025, 8:30 AM EDT - 1 year ago

Invivyd Earnings Call Transcript: Q1 2025

Invivyd Quarterly report: Q1 2025

May 15, 2025, 8:30 AM EDT - 1 year ago

Invivyd Quarterly report: Q1 2025

Invivyd Earnings release: Q1 2025

May 15, 2025, 8:30 AM EDT - 1 year ago

Invivyd Earnings release: Q1 2025

Invivyd Slides: Q1 2025

May 15, 2025, 8:30 AM EDT - 1 year ago

Invivyd Slides: Q1 2025

Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 15, 2025, 7:01 AM EDT - 1 year ago

Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights

Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy

May 14, 2025, 7:01 AM EDT - 1 year ago

Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy

Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

May 13, 2025, 7:01 AM EDT - 1 year ago

Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles

May 12, 2025, 7:01 AM EDT - 1 year ago

Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles

Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

May 8, 2025, 7:01 AM EDT - 1 year ago

Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

UserID123456
UserID123456 Jul. 3 at 1:21 PM
$IVVD Why is this up? In a purely politically motivated move (shocking) our idiotic leader of the HHS has officially ended all COVID-19 emergency use authorization declarations. They’re giving a 12-month “advance notice” / grace period to manufacturers of drugs or biological products, and a 6-month period to manufacturers of medical devices, to shift to full approval/clearance. That means Pemgarda is cooked.
1 · Reply
gb2017384
gb2017384 Jun. 29 at 3:08 PM
$IVVD DO THESE INSIDE TRADERS KNOW SOMETHING WE SHOULD$.
3 · Reply
gb2017384
gb2017384 Jun. 29 at 1:45 PM
$IVVD ,I KNOW IF THIS IVVD STOCK TAKES A DUMP THERES GOING TO BE ALOT OF BANKRUPT INVESTORS ÷$$$$$$$$$$$$$$$$$$$$$$$$$$$$$.
0 · Reply
billsmall
billsmall Jun. 26 at 10:25 PM
$IVVD OK at 3:59 there was a 22 mil share trade. Was that you Nik bringing your SLS profits over LOL (Congratulations by the way) I have to admit I'm a bit perplexed how this is trading. Anyone?
2 · Reply
Rynr
Rynr Jun. 25 at 2:34 AM
$IVVD silence before the storm
1 · Reply
student56
student56 Jun. 18 at 3:17 PM
$IVVD go higher
0 · Reply
Rollercoaster22
Rollercoaster22 Jun. 18 at 2:33 PM
$IVVD Very
0 · Reply
alexx013
alexx013 Jun. 18 at 2:26 PM
$IVVD dollar
0 · Reply
billsmall
billsmall Jun. 18 at 1:57 PM
$IVVD Someone smarter than me have a comment on why I'm seeing over 52k open $7.50 Puts? Not sure when they were written or bought just find it strange because no other strikes are anywhere near than in the near term
0 · Reply
Richi_B
Richi_B Jun. 18 at 11:03 AM
$IVVD had to average down at these prices. I will try and get more, this goes in circles. Back to around $2.50 in winter, hopefully more.
1 · Reply
Rollercoaster22
Rollercoaster22 Jun. 18 at 10:42 AM
$IVVD Nice recovery so far. Hope it continues. Does anybody know what happened before close three days in a row now? That sudden climb out of nowhere is really strange. In a good way. 😄
2 · Reply
alexx013
alexx013 Jun. 17 at 6:32 PM
$IVVD dollar soon
0 · Reply
billsmall
billsmall Jun. 17 at 6:07 PM
$IVVD Have not seen this in awhile. Under a million. Hummm... Fee Available Updated 0.3 % 550,000 2026-06-17 14:02:26 0.3 % 1,300,000 2026-06-17 13:46:52 0.3 % 1,300,000 2026-06-17 13:31:16 0.3 % 1,300,000 2026-06-17 13:15:38
0 · Reply
student56
student56 Jun. 17 at 3:27 PM
$IVVD go up and give me 25$+
1 · Reply
Rynr
Rynr Jun. 17 at 12:55 PM
$IVVD back above 1$ today
0 · Reply
student56
student56 Jun. 17 at 1:00 AM
$IVVD holding
1 · Reply
Cloudwatcher
Cloudwatcher Jun. 17 at 12:15 AM
$IVVD Why does the CEO keep sellijng shares???
3 · Reply
The_Big_DAWG
The_Big_DAWG Jun. 16 at 9:41 PM
$IVVD like this post if you think the Phase3 will be successful
0 · Reply
Rollercoaster22
Rollercoaster22 Jun. 16 at 1:57 PM
$IVVD Ok. This all make sense... 😂 Not. What a weird price action.
1 · Reply
DARKP00L
DARKP00L Jun. 16 at 1:23 PM
$IVVD 07:14 on Jun. 16 2026 Invivyd Completes Enrollment Phase 3 LIBERTY Trial Of Covid-19 Monoclonal Antibody VYD2311 With An mRNA Covid-19 Vaccine, Topline Data Expected in Q3 2026 #tradeideas
0 · Reply
tkstockpicker
tkstockpicker Jun. 16 at 12:25 AM
$IVVD jeebus
0 · Reply
Wanggamza
Wanggamza Jun. 15 at 11:56 PM
$IVVD whats going on?
0 · Reply